TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy

FEBS Letters

Volumn 588, Issue 16, 2014, Pages 2590-2599

  Costanzo, Antonio ^a   Pediconi, Natalia ^b,c   Narcisi, Alessandra ^a   Guerrieri, Francesca ^a,c   Belloni, Laura ^a,c   Fausti, Francesca ^a   Botti, Elisabetta ^a   Levrero, Massimo ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IIT Centre for Life Nanoscience (CLNS)   (Italy)

Author keywords

Development; TP53; TP63; TP73; Tumor suppressors

Indexed keywords

F BOX PROTEIN; FBXO45 PROTEIN; NAD(P)H QUINONE OXIDOREDUCTASE 1; NEDL2 PROTEIN; PEPTIDYLPROLYL ISOMERASE PIN1; PROTEIN MDM2; PROTEIN P53; PROTEIN P63; PROTEIN P73; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN 1;

ALTERNATIVE RNA SPLICING; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL METABOLISM; CHEMOSENSITIVITY; DNP63 GENE; DNP73 GENE; GENE EXPRESSION; NONHUMAN; OLIGOMERIZATION; ORGANOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTO ONCOGENE; REVIEW; SQUAMOUS CELL CARCINOMA; THERAPY RESISTANCE; TP63 GENE; TP73 GENE; TRANSCRIPTION REGULATION; TRANSLATION INITIATION; TUMOR SUPPRESSOR GENE;

DEVELOPMENT; TP53; TP63; TP73; TUMOR SUPPRESSORS;

ANIMALS; CARCINOGENESIS; DNA-BINDING PROTEINS; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84905085953     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2014.06.047     Document Type: Review

References (179)

1. M. Kaghad, H. Bonnet, and A. Yang et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers Cell 90 1997 809 819
2. A. Yang, M. Kaghad, and Y. Wang et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing and dominant-negative activities Mol. Cell 2 1998 305 316
3. A. Yang, R. Schweitzer, and D. Sun et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development Nature 398 1999 714 718
4. A.A. Mills, B. Zheng, X.J. Wang, and H. Vogel et al. p63 is a p53 homologue required for limb and epidermal morphogenesis Nature 398 1999 708 713
5. A. Yang, N. Walker, and R. Bronson et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours Nature 404 2000 99 103
6. M. Levrero, V. De Laurenzi, and A. Costanzo et al. The p53/p63/p73 family of transcription factors: overlapping and distinct functions J. Cell Sci. 113 2000 1661 1670
7. F. Murray-Zmijewski, D.P. Lane, and J.C. Bourdon p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress Cell Death Differ. 3 2006 962 972
8. P. Lunghi, A. Costanzo, and L. Mazzera et al. The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting Clin. Cancer Res. 15 2009 6495 6502
9. T. Stiewe The p53 family in differentiation and tumorigenesis Nat. Rev. Cancer 7 2007 165 168
10. E.R. Flores, S. Sengupta, and J.B. Miller et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family Cancer Cell 7 2005 363 373
11. X. Guo, W.M. Keyes, and C. Papazoglu et al. TAp63 induces senescence and suppresses tumorigenesis in vivo Nat. Cell Biol. 11 2009 1451 1457
12. R. Tomasini, K. Tsuchihara, and M. Wilhelm et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions Genes Dev. 22 2008 2677 2691
13. K. Harms, S. Nozell, and X. Chen The common and distinct target genes of the p53 family transcription factors Cell. Mol. Life Sci. 61 2004 822 842
14. T.S. Davison, C. Vagner, M. Kaghad, and A. Ayed et al. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53 J. Biol. Chem. 274 1999 18709 18714
15. A. Chikh, R.N. Matin, and V. Senatore et al. IASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia EMBO J. 30 2011 4261 4273
16. S. Surget, M.P. Khoury, and J.C. Bourdon Uncovering the role of p53 splice variants in human malignancy: a clinical perspective Onco Targets Ther. 7 2013 57 68
17. M. Sauer, A.C. Bretz, and R. Beinoraviciute-Kellner et al. C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity Nucleic Acids Res. 36 2008 1900 1912
18. V. De Laurenzi, A. Costanzo, and D. Barcaroli et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity J. Exp. Med. 188 1998 1763 1768
19. V.D. De Laurenzi, M.V. Catani, and A. Terrinoni et al. Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta Cell Death Differ. 6 1999 389 390
20. M. Irwin, M.C. Marin, and A.C. Phillips et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis Nature 407 2000 645 648
21. T. Stiewe, and B.M. Putzer Role of the p53-homologue p73 in E2F1-induced apoptosis Nat. Genet. 26 2000 464 469
22. R.S. Seelan, M. Irwin, and P. van der Stoop et al. The human p73 promoter: characterization and identification of functional E2F binding sites Neoplasia 4 2002 195 203
23. M. Marabese, F. Vikhanskaya, and C. Rainelli et al. DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1 Nucleic Acids Res. 31 2003 6624 6632
24. G. Fontemaggi, A. Gurtner, and S. Strano et al. The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation Mol. Cell. Biol. 21 2001 8461 8470
25. S. Wu, S. Murai, and K. Kataoka et al. Yin Yang 1 induces transcriptional activity of p73 through cooperation with E2F1 Biochem. Biophys. Res. Commun. 365 2008 75 81
26. T.J. Grob, U. Novak, and C. Maisse et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53 Cell Death Differ. 8 2001 1213 1223
27. S. Vossio, E. Palescandolo, and N. Pediconi et al. DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest Oncogene 21 2002 3796 3803
28. N.N. Kartasheva, A. Contente, and C. Lenz-Stoppler et al. P53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop Oncogene 21 2002 4715 4727
29. T. Nakagawa, M. Takahashi, and T. Ozaki et al. Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter Mol. Cell. Biol. 22 2002 2575 2585
30. J. Castillo, S. Goñi, and M.U. Latasa et al. Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors Gastroenterology 137 2009 1805 1815 (e1-4)
31. M. Rossi, V. De Laurenzi, and E. Munarriz et al. The ubiquitin-protein ligase Itch regulates p73 stability EMBO J. 24 2005 836 848
32. M. Rossi, R.I. Aqeilan, and M. Neale et al. The E3 ubiquitin ligase Itch controls the protein stability of p63 Proc. Natl. Acad. Sci. USA 103 2006 12753 12758
33. D. Levy, Y. Adamovich, and N. Reuven et al. The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73 Cell Death Differ. 14 2007 743 751
34. M. Dobbelstein, S. Wienzek, and C. Konig et al. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein Oncogene 18 1999 2101 2106
35. X. Zeng, L. Chen, and C.A. Jost et al. MDM2 suppresses p73 function without promoting p73 degradation Mol. Cell. Biol. 19 1999 3257 3266
36. I.R. Watson, A. Blanch, and D.C. Lin et al. Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function J. Biol. Chem. 281 2006 34096 34103
37. F. Galli, M. Rossi, and Y. D'Alessandra et al. MDM2 and Fbw7 cooperate to induce p63 protein degradation following DNA damage and cell differentiation J. Cell Sci. 123 2010 2423 2433
38. A. Peschiaroli, F. Scialpi, and F. Bernassola et al. The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73 Oncogene 28 2009 3157 3166
39. M. Hosoda, T. Ozaki, and K. Miyazaki et al. UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination Oncogene 24 2005 7156 7169
40. K. Miyazaki, T. Ozaki, and C. Kato et al. A novel HECT-type E3 ubiquitin ligase, NEDL2, stabilizes p73 and enhances its transcriptional activity Biochem. Biophys. Res. Commun. 308 2003 106 113
41. G. Asher, J. Lotem, and L. Sachs et al. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1 Proc. Natl. Acad. Sci. USA 99 2002 13125 13130
42. C. Li, D.L. Chang, Z. Yang, and J. Qi et al. Pin1 modulates p63α protein stability in regulation of cell survival, proliferation and tumor formation Cell Death Dis. 4 2013 e943 (Dec 5)
43. M. Restelli, T. Lopardo, and N. Lo Iacono et al. DLX5, FGF8 and the Pin1 isomerase control ΔNp63α protein stability during limb development: a regulatory loop at the basis of the SHFM and EEC congenital malformations Hum. Mol. Genet. 2014 (Feb 25, Epub ahead of print)
44. W.H. Toh, M.M. Siddique, and L. Boominathan et al. C-Jun regulates the stability and activity of the p53 homologue, p73 J. Biol. Chem. 279 2004 44713 44722
45. I. Dulloo, G. Gopalan, and G. Melino et al. The antiapoptotic DeltaNp73 is degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-mediated pathway Proc. Natl. Acad. Sci. USA 107 2010 4902 4907
46. B.S. Sayan, A.L. Yang, and F. Conforti et al. Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2 Proc. Natl. Acad. Sci. USA 107 2010 12877 12882
47. Y.S. Jung, Y. Qian, and W. Yan et al. Pirh2 E3 ubiquitin ligase modulates keratinocyte differentiation through p63 J. Invest. Dermatol. 133 2013 1178 1187
48. R.A. Robinson, X. Lu, E.Y. Jones, and C. Siebold Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73 Structure 16 2008 259 268
49. D. Bergamaschi, Y. Samuels, and A. Sullivan et al. IASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53 Nat. Genet. 38 2006 1133 1141
50. D. Bergamaschi, Y. Samuels, and B. Jin et al. ASPP1 and ASPP2: common activators of p53 family members Mol. Cell. Biol. 24 2004 1341 1350
51. T. Rinne, B. Hamel, and H. van Bokhoven et al. Pattern of p63 mutations and their phenotypes-update Am. J. Med. Genet. A 140 2006 1396 1406
52. L. Guerrini, A. Costanzo, and G.R. Merlo A symphony of regulations centered on p63 to control development of ectoderm-derived structures J. Biomed. Biotechnol. 2011 2011 864904
53. H. van Bokhoven, and H.G. Brunner Splitting p63 Am. J. Hum. Genet. 71 2002 1 13
54. J.A. McGrath, P.H. Duijf, and V. Doetsch et al. Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63 Hum. Mol. Genet. 10 2001 221 229
55. M. Senoo, F. Pinto, and C.P. Crum et al. P63 Is essential for the proliferative potential of stem cells in stratified epithelia Cell 129 2007 523 536
56. W.M. Keyes, Y. Wu, and H. Vogel et al. P63 deficiency activates a program of cellular senescence and leads to accelerated aging Genes Dev. 19 2005 1986 1999
57. X. Su, M. Paris, and Y.J. Gi et al. TAp63 prevents premature aging by promoting adult stem cell maintenance Cell Stem Cell 5 2009 64 75
58. A. Medawar, T. Virolle, and P. Rostagno et al. DeltaNp63 is essential for epidermal commitment of embryonic stem cells PLoS One 3 2008 e3441
59. J. Laurikkala, M.L. Mikkola, and M. James et al. P63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation Development 133 2006 1553 1563
60. E.K. Suh, A. Yang, and A. Kettenbach et al. P63 protects the female germ line during meiotic arrest Nature 444 2006 624 628
61. M.I. Koster, S. Kim, and A.A. Mills et al. P63 is the molecular switch for initiation of an epithelial stratification program Genes Dev. 18 2004 126 131
62. M.I. Koster, D. Dai, and B. Marinari et al. p63 induces key target genes required for epidermal morphogenesis Proc. Natl. Acad. Sci. USA 104 2007 3255 3260
63. K.E. King, R.M. Ponnamperuma, and T. Yamashita et al. DNp63alpha functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes Oncogene 22 2003 3635 3644
64. B.C. Nguyen, K. Lefort, and A. Mandinova et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation Genes Dev. 20 2006 1028 1042
65. F. Moretti, B. Marinari, and N. Lo Iacono et al. A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias J. Clin. Invest. 120 2010 1570 1577
66. A. Di Costanzo, L. Festa, and O. Duverger et al. Homeodomain protein Dlx3 induces phosphorylation-dependent p63 degradation Cell Cycle 8 2009 1185 1195
67. F. Moretti, and A. Costanzo A feedback regulatory loop between p63 and Dlx3: implications for epidermal differentiation Cell Cycle 8 2009 1113
68. R. Yi, M.N. Poy, M. Stoffel, and E. Fuchs A skin microRNA promotes differentiation by repressing 'stemness' Nature 452 2008 225 229
69. J.M. Hearnes, D.J. Mays, and K.L. Schavolt et al. Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators Mol. Cell. Biol. 25 2005 10148 10158
70. M. Papoutsaki, F. Moretti, and M. Lanza et al. A p38-dependent pathway regulates DeltaNp63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes Oncogene 24 2005 6970 6975
71. E.A. Ratovitski Phospho-ΔNp63α regulates AQP3, ALOX12B, CASP14 and CLDN1 expression through transcription and microRNA modulation FEBS Lett. 587 2013 3581 3586
72. B. Marinari, C. Ballaro, and M.I. Koster et al. IKKalpha is a p63 transcriptional target involved in the pathogenesis of ectodermal dysplasias J. Invest. Dermatol. 129 2009 60 69
73. V.G. Beaudry, N. Pathak, M.I. Koster, and L.D. Attardi Differential PERP regulation by TP63 mutants provides insight into AEC pathogenesis Am. J. Med. Genet. A 149A 2009 1952 1957
74. T. Sen, X. Chang, and D. Sidransky et al. Regulation of ΔNp63α by NF-κB Cell Cycle 9 2010 24
75. A.K. Sil, S. Maeda, Y. Sano, and D.R. Roop et al. IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis Nature 428 2004 660 664
76. P. Descargues, A.K. Sil, and Y. Sano et al. IKKalpha is a critical coregulator of a Smad4-independent TGFbeta-Smad2/3 signaling pathway that controls keratinocyte differentiation Proc. Natl. Acad. Sci. USA 105 2008 2487 2492
77. B. Marinari, F. Moretti, and E. Botti et al. The tumor suppressor activity of IKKalpha in stratified epithelia is exerted in part via the TGF-beta antiproliferative pathway Proc. Natl. Acad. Sci. USA 105 2008 17091 17096
78. H.A. Thomason, H. Zhou, and E.N. Kouwenhoven et al. Cooperation between the transcription factors p63 and IRF6 is essential to prevent cleft palate in mice J. Clin. Invest. 120 2010 1561 1569
79. H.A. Thomason, M.J. Dixon, and J. Dixon Facial clefting in Tp63 deficient mice results from altered Bmp4, Fgf8 and Shh signaling Dev. Biol. 321 2008 273 282
80. A. Bagchi, and A.A. Mills The quest for the 1p36 tumor suppressor Cancer Res. 68 2008 2551 2556
81. M.S. Irwin, and W.G. Kaelin Jr. Role of the newer p53 family proteins in malignancy Apoptosis 6 2001 17 29
82. G. Melino, V. De Laurenzi, and K.H. Vousden p73: friend or foe in tumorigenesis Nat. Rev. Cancer 2 2002 605 615
83. G. Fontemaggi, I. Kela, and N. Amariglio et al. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses J. Biol. Chem. 277 2002 43359 43368
84. O. Petrenko, A. Zaika, and U.M. Moll DeltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo Mol. Cell. Biol. 23 2003 5540 5555
85. P.G. Corn, S.J. Kuerbitz, and M.M. van Noesel et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation Cancer Res. 59 1999 3352 3356
86. S. Kawano, C.W. Miller, and A.F. Gombart et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation Blood 94 1999 1113 1120
87. W.M. Keyes, H. Vogel, and M.I. Koster et al. P63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors Proc. Natl. Acad. Sci. USA 103 2006 8435 8440
88. R.A. Romano, K. Smalley, and C. Magraw et al. ΔNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation Development 4 2012 772 782
89. E. Park, H. Kim, J.M. Kim, B. Primack, S. Vidal-Cardenas, Y. Xu, B.D. Price, A.A. Mills, and A.D. D'Andrea FANCD2 activates transcription of TAp63 and suppresses tumorigenesis Mol. Cell 50 2013 908 918
90. R. Tomasini, V. Secq, and L. Pouyet et al. TAp73 is required for macrophage-mediated innate immunity and the resolution of inflammatory responses Cell Death Differ. 20 2013 293 301
91. L. Holembowski, D. Kramer, and D. Riedel et al. TAp73 is essential for germ cell adhesion and maturation in testis J. Cell Biol. 204 2014 1173 1190
92. S. Inoue, R. Tomasini, and A. Rufini et al. TAp73 is required for spermatogenesis and the maintenance of male fertility Proc. Natl. Acad. Sci. USA 111 2014 1843 1848
93. R. Tomasini, K. Tsuchihara, and C. Tsuda et al. TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity Proc. Natl. Acad. Sci. USA 106 2009 797 802
94. M. Fulco, A. Costanzo, and P. Merlo et al. P73 is regulated by phosphorylation at the G2/M transition J. Biol. Chem. 278 2003 49196 49202
95. P. Merlo, M. Fulco, and A. Costanzo et al. A role of p73 in mitotic exit J. Biol. Chem. 80 2005 30354 30360
96. F. Talos, A. Nemajerova, and E.R. Flores et al. P73 suppresses polyploidy and aneuploidy in the absence of functional p53 Mol. Cell 27 2007 647 659
97. H. Griesmann, K. Schlereth, and M. Krause et al. P53 and p73 in suppression of Myc-driven lymphomagenesis Int. J. Cancer 124 2009 502 506
98. A. Nemajerova, O. Petrenko, and L. Trumper et al. Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice J. Clin. Invest. 120 2010 2070 2080
99. D. Kenzelmann Broz, and S. Spano Mello et al. Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses Genes Dev. 27 2013 1016 1031
100. E.R. Flores, K.Y. Tsai, and D. Crowley et al. P63 and p73 are required for p53-dependent apoptosis in response to DNA damage Nature 416 2002 560 564
101. O.D. Maddocks, and K.H. Vousden Metabolic regulation by p53 J. Mol. Med. 89 2011 237 245
102. X. Su, Y.J. Gi, and D. Chakravarti et al. TAp63 is a master transcriptional regulator of lipid and glucose metabolism Cell Metab. 16 2012 511 525
103. Z. He, H. Liu, and M. Agostini et al. p73 regulates autophagy and hepatocellular lipid metabolism through a transcriptional activation of the ATG5 gene Cell Death Differ. 20 2013 1415 1424
104. J.R. Cantor, and D.M. Sabatini Cancer cell metabolism: one hallmark, many faces Cancer Discov. 10 2012 881 898
105. W. Du, P. Jiang, and A. Mancuso et al. TAp73 enhances the pentose phosphate pathway and supports cell proliferation Nat. Cell Biol. 15 2013 991 1000
106. A. Rufini, M.V. Niklison-Chirou, and S. Inoue et al. TAp73 depletion accelerates aging through metabolic dysregulation Genes Dev. 26 2012 2009 2014
107. P. Jiang, W. Du, and X. Wang et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase Nat. Cell Biol. 13 2011 310 316
108. K. Bensaad, A. Tsuruta, and M.A. Selak et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis Cell 126 1 2006 107 120
109. E.C. Cheung, D. Athineos, and P. Lee et al. TIGAR is required for efficient intestinal regeneration and tumorigenesis Dev. Cell 25 2013 463 477
110. T. Velletri, F. Romeo, and P. Tucci et al. GLS2 is transcriptionally regulated by p73 and contributes to neuronal differentiation Cell Cycle 12 2013 3564 3573
111. I. Amelio, E.K. Markert, and A. Rufini et al. p73 regulates serine biosynthesis in cancer Oncogene 2013 10.1038/onc.2013.456 (Nov 4, Epub ahead of print)
112. A. Giacobbe, L. Bongiorno-Borbone, and F. Bernassola et al. p63 regulates glutaminase 2 expression Cell Cycle 12 2013 1395 1405
113. S. Suzuki, T. Tanaka, and M.V. Poyurovsky et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species Proc. Natl. Acad. Sci. USA 107 2010 7461 7466
114. W. Hu, C. Zhang, and R. Wu et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function Proc. Natl. Acad. Sci. USA 107 2010 7455 7460
115. O.D. Maddocks, and K.H. Vousden Metabolic regulation by p53 J. Mol. Med. 2011 89 2011 237 245
116. J. Son, C.A. Lyssiotis, and H. Ying et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway Nature 496 2013 101 105
117. P. Jiang, W. Du, A. Mancuso, K.E. Wellen, and X. Yang Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence Nature 493 2013 689 693
118. P. Jiang, W. Du, and X. Yang A critical role of glucose-6-phosphate dehydrogenase in TAp73-mediated cell proliferation Cell Cycle 12 2013 3720 3726
119. K. Lefkimmiatis, M.F. Caratozzolo, and P. Merlo et al. p73 and p63 sustain cellular growth by transcriptional activation of cell cycle progression genes Cancer Res. 69 2009 8563 8571
120. E. Sbisà, G. Mastropasqua, and K. Lefkimmiatis et al. Connecting p63 to cellular proliferation: the example of the adenosine deaminase target gene Cell Cycle 2 2006 205 212
121. C.P. Lau, P.K. Ng, and M.S. Li et al. p63 regulates cell proliferation and cell cycle progression-associated genes in stromal cells of giant cell tumor of the bone Int. J. Oncol. 42 2013 437 443
122. M.S. Irwin, K. Kondo, and M. Marin Jr. et al. Chemosensitivity linked to p73 function Cancer Cell 3 2003 403 410
123. N. Pediconi, A. Ianari, and A. Costanzo et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damage Nat. Cell Biol. 5 2003 552 558
124. T. Ozaki, R. Okoshi, and M. Sang et al. Acetylation status of E2F-1 has an important role in the regulation of E2F-1-mediated transactivation of tumor suppressor p73 Biochem. Biophys. Res. Commun. 386 2009 207 211
125. M. Urist, T. Tanaka, and M.V. Poyurovsky et al. P73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2 Genes Dev. 18 2004 3041 3054
126. N. Pediconi, F. Guerrieri, and S. Vossio et al. HSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage Mol. Cell. Biol. 29 2009 1989 1998
127. H. Kontaki, and I. Talianidis Lysine methylation regulates E2F1-induced cell death Mol. Cell 39 2010 152 160
128. R. Agami, G. Blandino, and M. Oren et al. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis Nature 399 1999 809 813
129. J.G. Gong, A. Costanzo, and H.Q. Yang et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage Nature 399 1999 806 809
130. Z.M. Yuan, H. Shioya, and T. Ishiko et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage Nature 399 1999 814 817
131. S. Gonzalez, C. Prives, and C. Cordon-Cardo p73alpha regulation by Chk1 in response to DNA damage Mol. Cell. Biol. 23 2003 8161 8171
132. J. Ren, R. Datta, and H. Shioya et al. p73beta is regulated by protein kinase Cdelta catalytic fragment generated in the apoptotic response to DNA damage J. Biol. Chem. 277 2002 33758 33765
133. E.V. Jones, M.J. Dickman, and A.J. Whitmarsh Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase Biochem. J. 05 2007 617 623
134. R. Sanchez-Prieto, V.J. Sanchez-Arevalo, and J.M. Servitja et al. Regulation of p73 by c-Abl through the p38 MAP kinase pathway Oncogene 21 2002 974 979
135. R. Baskaran, L.D. Wood, and L.L. Whitaker et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation Nature 387 1997 516 519
136. K. Yoshida, T. Ozaki, and K. Furuya et al. ATM-dependent nuclear accumulation of IKK-alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin Oncogene 27 2008 1183 1188
137. K. Furuya, T. Ozaki, and T. Hanamoto et al. Stabilization of p73 by nuclear IkappaB kinase-alpha mediates cisplatin-induced apoptosis J. Biol. Chem. 282 2007 18365 18378
138. S. Strano, O. Monti, and N. Pediconi et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage Mol. Cell 18 2005 447 459
139. S. Strano, E. Munarriz, and M. Rossi et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity J. Biol. Chem. 276 2001 15164 15173
140. S. Basu, N.F. Totty, and M.S. Irwin et al. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis Mol. Cell 11 2003 11 23
141. A. Costanzo, P. Merlo, and N. Pediconi et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes Mol. Cell 9 2002 175 186
142. F. Mantovani, S. Piazza, and M. Gostissa et al. Pin1 links the activities of c-Abl and p300 in regulating p73 function Mol. Cell 14 2004 625 636
143. J.W. Rocco, C.O. Leong, and N. Kuperwasser et al. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis Cancer Cell 9 2006 45 56
144. C.O. Leong, N. Vidnovic, M.P. DeYoung, D. Sgroi, and L.W. Ellisen The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers J. Clin. Invest. 117 2007 1370 1380
145. M.C. Marin, C.A. Jost, and L.A. Brooks et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour Nat. Genet. 25 2000 47 54
146. D. Bergamaschi, M. Gasco, and L. Hiller et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis Cancer Cell 3 2003 387 402
147. P. Dumont, J.I. Leu, and A.C. Della Pietra et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential Nat. Genet. 33 2003 357 365
148. M. Tada, K. Furuuchi, and M. Kaneda et al. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants Carcinogenesis 22 2001 515 517
149. O. Ishimoto, C. Kawahara, and K. Enjo et al. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73 Cancer Res. 62 2002 636 641
150. T. Stiewe, S. Zimmermann, and A. Frilling et al. Transactivation- deficient DeltaTA-p73 acts as an oncogene Cancer Res. 62 2002 3598 3602
151. A. Tannapfel, K. John, and N. Mise et al. Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73 Carcinogenesis 29 2008 211 218
152. A.I. Zaika, N. Slade, and S.H. Erster et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors J. Exp. Med. 196 2002 765 780
153. T. Stiewe, J. Stanelle, and C.C. Theseling et al. Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73 J. Biol. Chem. 278 2003 14230 14236
154. H. Cam, H. Griesmann, and M. Beitzinger et al. p53 family members in myogenic differentiation and rhabdomyosarcoma development Cancer Cell 10 2006 281 293
155. W.H. Toh, E. Logette, and L. Corcos et al. TAp73beta and DNp73beta activate the expression of the pro-survival caspase-2S Nucleic Acids Res. 36 2008 4498 4509
156. M. Lanza, B. Marinari, and M. Papoutsaki et al. Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-of-function mutants Cell Cycle 5 2006 1996 2004
157. N.N. Kartasheva, C. Lenz-Bauer, and O. Hartmann et al. DeltaNp73 can modulate the expression of various genes in a p53-independent fashion Oncogene 22 2003 8246 8254
158. K. Becker, P. Pancoska, and N. Concin et al. Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers Int. J. Oncol. 29 2006 889 902
159. N. Concin, K. Becker, and N. Slade et al. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer Evidence for their role as epigenetic p53 inhibitors in vivo Cancer Res. 64 2004 2449 2460
160. M. Guan, and Y. Chen Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score J. Clin. Pathol. 58 2005 1175 1179
161. S. Tuve, S.N. Wagner, and B. Schittek et al. Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression Int. J. Cancer 108 2004 162 166
162. I. Casciano, K. Mazzocco, and L. Boni et al. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients Cell Death Differ. 9 2002 246 251
163. T. Stiewe, S. Tuve, and M. Peter et al. Quantitative TP73 transcript analysis in hepatocellular carcinomas Clin. Cancer Res. 10 2004 626 633
164. M. Muller, T. Schilling, and A.E. Sayan et al. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma Cell Death Differ. 12 2005 1564 1577
165. S. Buhlmann, and B.M. Putzer DNp73 a matter of cancer: mechanisms and clinical implications Biochim. Biophys. Acta 1785 2008 207 216
166. M. Beitzinger, L. Hofmann, and C. Oswald et al. P73 poses a barrier to malignant transformation by limiting anchorage-independent growth EMBO J. 27 2008 792 803
167. M. Steder, V. Alla, and C. Meier et al. DNp73 exerts function in metastasis initiation by disconnecting the inhibitory role of EPLIN on IGF1R-AKT/STAT3 signaling Cancer Cell 24 2013 512 527
168. M.D. Westfall, and J.A. Pietenpol p63: molecular complexity in development and cancer Carcinogenesis 25 2004 857 864
169. G. Wu, M. Osada, and Z.F. Guo et al. DNp63a up-regulates the Hsp70 gene in human cancer Cancer Res. 65 2005 758 766
170. S. Patel, R. George, and F. Autore et al. Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax Nucleic Acids Res. 36 2008 5139 5151
171. C. Lazzari, A. Prodosmo, and F. Siepi et al. HIPK2 phosphorylates ΔNp63α and promotes its degradation in response to DNA damage Oncogene 30 2011 4802 4813
172. E. Botti, G. Spallone, and F. Moretti et al. Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas Proc. Natl. Acad. Sci. 108 2011 13710 13715
173. B. Marinari, F. Moretti, and E. Botti et al. The tumor suppressor activity of IKKalpha in stratified epithelia is exerted in part via the TGF-beta antiproliferative pathway Proc. Natl. Acad. Sci. USA 105 2008 17091 17096
174. M.R. Ramsey, C. Wilson, and B. Ory et al. FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma J. Clin. Invest. 123 2013 3525 3538
175. P. Descargues, A.K. Sil, and M. Karin IKKalpha, a critical regulator of epidermal differentiation and a suppressor of skin cancer EMBO J. 27 2008 2639 2647
176. B. Liu, E. Park, and F. Zhu et al. A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas Proc. Natl. Acad. Sci. USA 103 2006 17202 17207
177. Y. Hu, V. Baud, and T. Oga et al. IKKalpha controls formation of the epidermis independently of NF-kappaB Nature 410 2001 710 714
178. G. Restivo, B.C. Nguyen, and P. Dziunycz et al. IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes EMBO J. 30 2011 4571 4585
179. M.T. Wilhelm, A. Rufini, and M.K. Wetzel et al. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway Genes Dev. 24 2010 549 560